Novavax Inc
Most Recent
Novavax Vaccine Is Spearheaded by Institutional Investors
Novavax Combined Vaccine Explained, NVAX Stock Looks Iffy
Novavax Inches Closer to COVID-19 Vaccine, Stock Reacts to Updates
Is Novavax Stock a Good Buy at This Price?
Novavax Stock Jumps Due to COVID-19 Vaccine Trial Results
Pfizer Soars Due to Hopes about a Coronavirus Vaccine
Pfizer (NYSE:PFE) stock rose 2.4% in pre-market trading at 7:51 AM ET today. The company’s experimental COVID-19 vaccine showed positive results.
Can You Still Get a Piece of Norwegian Cruise Line Stock?
Today at 6:22 AM ET, Norwegian Cruise Line Holdings (NASDAQ:NCLH) stock rose 12% to $17.90 in the pre-market session. What can investors expect?
Buy Carnival Stock before It Makes Another Big Move
Today at 6:32 AM ET, Carnival (NYSE:CCL) stock rose 11% to $16.00 in the pre-market session. The company has been benefiting from positive developments.
Novavax Soared 20% on Coronavirus Vaccine Hopes
Today at 4:37 AM ET, Novavax stock rose 20% to $55.40 in the pre-market session. The company started the Phase I study of NVX-CoV2373.
Could Certain Marijuana Strains Help Fight COVID-19?
The cannabis industry is doing its own research amid COVID-19. Researchers discovered that marijuana might have properties to fight the coronavirus.
Is Carnival Stock Worth Your Attention Right Now?
Carnival stock rose 15.2% on Monday and closed at $14.72 with a market cap of $10.7 billion. The stock price rose due to hope about a COVID-19 vaccine.
Coronavirus Vaccine: Novavax and Moderna Lead the Race
Novavax stock rose almost 133% in the week ended May 15 and closed at $43.63. The stock has generated returns of 552% in the last 12 months.
Novavax Rose 38% Due to $384 Million COVID-19 Funding
Today at 4:30 AM ET, Novavax stock rose 38% to $33.74 in the pre-market session. The company received funding for its COVID-19 vaccine candidate.
NanoFlu Vaccine Could Be Big Growth Opportunity for Novavax
On January 3, Novavax (NVAX) issued a press release announcing positive results from a Phase 2 trial that compared multiple quadrivalent formulations of its Nanoflu vaccine.
Will the ResVax Vaccine Be Key Revenue Driver for Novavax?
On February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM.
What Analysts Are Recommending for Novavax after Q1 Results
Novavax (NVAX) reported first-quarter results on May 2.
Why Novavax Is Tanking Today
Today, Novavax (NVAX) is trading close to $0.70, which is about 67.13% lower than its previous closing price.
Amarin or Novavax: Who’s Controlling Expenses Better?
In its investor presentation, Amarin (AMRN) highlighted the United States as its priority target market for commercializing Vascepa.
Amarin or Novavax: Which Will Report Faster EPS Growth?
In its investor presentation, Amarin (AMRN) highlighted the annual death toll attributable to cardiovascular disease in the United States to more than 800,000 while the yearly treatment cost is estimated at $555 billion.
Amarin or Novavax: Which Will Report Faster Revenue Growth?
With its 2018 unaudited results, as announced in an investor presentation, Amarin (AMRN) has guided for net total revenue in the range of $72 million–$76 million…
What Wall Street Recommends for Amarin and Novavax
On February 22, Amarin (AMRN) closed at $19.87, 14% higher than its previous closing price and 746% higher than its 52-week low of $2.35.
Novavax Rose Due to Positive NanoFlu Vaccine Results
On January 3, Novavax (NVAX) issued a press release announcing positive top-line results from NanoFlu vaccine Phase 2 trial.
Novavax’s ResVax Vaccine Could Be Blockbuster Market Opportunity
Novavax expects the peak revenue opportunity for its ResVax maternal immunization vaccine to be ~$750 million in the United States.
ResVax Vaccine Program Is Novavax’s Key Growth Driver in 2018
Novavax (NVAX) completed enrollment of its ResVax infant vaccine program through maternal immunization in the second quarter of 2018.
Novavax Expected to Report Solid Revenue Growth in Fiscal 2018
Wall Street analysts expect Novavax to report revenues of $36.36 million in fiscal 2018, which is a YoY (year-over-year) rise of 21.86%.
Gauging Analysts’ Expectations for Novavax and Peers in August
Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.
Why Novavax Sees a Huge Opportunity in Its Influenza Vaccine
Novavax (NVAX) expects the seasonal influenza vaccine market in the world’s top seven markets to grow from ~$3.2 billion in the 2012–2013 season to $5.3 billion by the 2021–2022 season.
How Much Upside Analysts See In Novavax Stock
Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market.
How Analysts View Agios Pharmaceuticals and Peers in March 2018
Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.
Analysts’ Ratings for Sorrento and Its Peers in March 2018
Of the two analysts covering Sorrento Therapeutics in March 2018, one analyst has given it a “strong buy” recommendation.
What Analysts Recommend for AbbVie and Peers in March 2018
Of the 23 analysts covering AbbVie in March 2018, four analysts have given the stock a “strong buy,” six have given it a “buy,” 12 have given it a “hold,” and one has given it a “sell.”
What’s behind Omeros’s Cash Flow
In fiscal 2017, Omeros spent $36.2 million on operating activities, compared with $51.5 million in fiscal 2016.
Analysts’ Ratings for Omeros and Peers in March 2018
Omeros (OMER) is a commercial biopharmaceutical company. Its product, Omidria, is used in cataract surgery.
Exploring Xencor’s Cash Flows
Xencor (XNCR) used $33.6 million in operating activities in 2017. In 2016, the company generated $94.6 million from operating activities.
Analysts’ Recommendations for Xencor and Its Peers in March
Of the six analysts covering Xencor in March 2018, three have given the stock “strong buy” ratings.
A Strong Product Pipeline Bodes Well for Novavax
Novavax’s nanoparticle influenza vaccine (or NanoFlu) is currently in Phase 1 and Phase 2 development.
Analyzing Novavax’s Cash Flows
Novavax generated $64.5 million from financing activities in fiscal 2017 compared with $279.0 million in fiscal 2016.
Chart in Focus: Novavax’s Financial Position in 2017
Novavax (NVAX) generated revenues of $8.4 million in 3Q17 compared with $3.2 million in 3Q16.
An Overview of Novavax’s Influenza and Ebola Vaccines
According to Novavax (NVAX), the value of the influenza vaccine market in developed markets is expected to reach $5.3 billion by 2021–2022 compared with $3.2 billion in 2012–2013.
Exploring Novavax’s Vaccine Candidates for RSV
According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.
Inside Analysts’ Recommendations for Novavax in November 2017
A clinical-stage biotech company, Novavax’s (NVAX) pipeline includes products for influenza, Ebola virus, and Zika virus. In November, two of seven analysts gave NVAX stock a “strong buy” rating.
How Are Eli Lilly’s Business Segments Performing?
Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.
Bristol-Myers Squibb’s 2Q16 Estimates: Expect Growth!
Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.
XBI’s Holdings: What’s the Trend in Its Moving Averages?
On June 15, 2016, XBI closed at $54.74. It was trading above its 20-day and 50-day moving averages. XBI’s 20-day moving average is $56.30.
Incyte Continues Its Growth Spree in 2015
Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.
XBI Rises in Contrast to a Flat Market
XBI closed at $68.65 on November 17, 2015. Out of XBI’s 101 holdings, 70 stocks ended with positive returns, while 31 stocks ended in the red.
Kite Led Top Ten Stocks by Weight in XBI’s Biotechnology Subgroup
Kite Pharma (KITE), which has a weight of 1.17% in the SPDR S&P Biotechnology ETF (XBI), rose 21.94% for the week ended September 11.
Benchmark Indexes Continue to Outperform IBB and XBI
The iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) provide investors with an opportunity to hold a basket of stocks from different subindustries from the biotech sector.
How Does Novavax Compare to Its Competitors?
Novavax posted a negative EPS (earnings per share) of -$0.39 in 2Q15, which is better than its 1Q15 EPS.
How Did Novavax Perform in 2Q15?
Novavax (NVAX) posted a variety of positive qualitative and quantitative performance indicators in 2Q15.
PJP and PBE Are Sectoral Smart Beta Funds
The PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) is a smart beta fund that tracks the performance of the Dynamic Pharmaceutical Intellidex Index.
